- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
73
73 companies
Zevra Therapeutics
Market Cap: US$714.7m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$13.66
7D
25.6%
1Y
47.2%
Madrigal Pharmaceuticals
Market Cap: US$10.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$476.89
7D
5.3%
1Y
68.9%
Beijing Luzhu Biotechnology
Market Cap: HK$2.5b
A biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.
2480
HK$12.50
7D
-25.1%
1Y
-45.7%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$93.6b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$401.40
7D
0.7%
1Y
17.0%
Camurus
Market Cap: SEK 32.5b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 543.50
7D
2.8%
1Y
-15.8%
Syndax Pharmaceuticals
Market Cap: US$1.5b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$17.69
7D
-3.8%
1Y
57.4%
Oscotec
Market Cap: ₩1.5t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩38,950.00
7D
-7.3%
1Y
40.6%
Kuros Biosciences
Market Cap: CHF 773.0m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 19.60
7D
4.1%
1Y
-26.8%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 225.40
7D
0.6%
1Y
-15.9%
HansBiomed
Market Cap: ₩336.6b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩23,600.00
7D
-10.3%
1Y
134.4%
AnaptysBio
Market Cap: US$1.5b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$51.63
7D
0.7%
1Y
115.4%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.60
7D
1.4%
1Y
49.7%
Cutia Therapeutics
Market Cap: HK$1.2b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$3.24
7D
-8.7%
1Y
-73.9%
Forum Markets
Market Cap: US$77.2m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$5.22
7D
9.4%
1Y
-49.8%
Alnylam Pharmaceuticals
Market Cap: US$39.0b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$297.69
7D
4.0%
1Y
-1.6%
Pharma Mar
Market Cap: €1.5b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€83.80
7D
-12.8%
1Y
-8.6%
ARS Pharmaceuticals
Market Cap: US$892.7m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$9.41
7D
5.7%
1Y
-35.9%
Aldeyra Therapeutics
Market Cap: US$105.0m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.72
7D
4.9%
1Y
-35.9%
Capricor Therapeutics
Market Cap: US$1.5b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$26.01
7D
-4.9%
1Y
87.3%
Intellia Therapeutics
Market Cap: US$1.9b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$12.89
7D
-1.8%
1Y
52.2%
Ocumension Therapeutics
Market Cap: HK$4.4b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$5.35
7D
-6.1%
1Y
-40.8%
Clinuvel Pharmaceuticals
Market Cap: AU$439.7m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$8.72
7D
-1.2%
1Y
-15.8%
Bide Pharmatech
Market Cap: CN¥3.9b
Engages in the research, development, production, and sale of pharmaceutical products in China.
688073
CN¥45.55
7D
-6.9%
1Y
-8.2%
MindMaze Therapeutics Holding
Market Cap: CHF 50.7m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.33
7D
-12.3%
1Y
n/a
Arcutis Biotherapeutics
Market Cap: US$2.7b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$22.79
7D
9.6%
1Y
64.1%
Oxford Biomedica
Market Cap: UK£740.0m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.12
7D
6.4%
1Y
83.5%
CG Oncology
Market Cap: US$4.8b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$56.67
7D
2.1%
1Y
106.2%
BioStem Technologies
Market Cap: US$65.2m
Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
BSEM
US$3.57
7D
-14.5%
1Y
-74.6%
Kiniksa Pharmaceuticals International
Market Cap: US$3.8b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$48.70
7D
3.8%
1Y
63.6%
May & Baker Nigeria
Market Cap: ₦81.1b
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria.
MAYBAKER
₦47.00
7D
-2.1%
1Y
235.7%
Bora Pharmaceuticals
Market Cap: NT$50.5b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$398.00
7D
12.4%
1Y
-42.0%
Belite Bio
Market Cap: US$5.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$141.42
7D
4.8%
1Y
131.1%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.20
7D
-4.5%
1Y
-26.6%
Devyser Diagnostics
Market Cap: SEK 1.6b
Provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
DVYSR
SEK 94.60
7D
2.8%
1Y
-16.4%
NewAmsterdam Pharma
Market Cap: US$3.6b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$30.38
7D
-4.2%
1Y
39.1%
SIGA Technologies
Market Cap: US$310.6m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.39
7D
1.6%
1Y
-29.4%